DALLAS, June 29, 2005 (PRIMEZONE) -- A new research note on Xenomics Inc (OTCBB:XNOM) has been released on Beacon Equity Research. The report is written by Senior Analyst, Shailesh Dhuri, CFA.
In the report, Mr. Dhuri writes, "Xenomics Inc is an early stage molecular diagnostic company that has developed a patented Transrenal DNA (Tr-DNA -- residual DNA in urine) technology to test urine specimens for genetic analyses. The Company's objective is simply to change the dynamics of the medical diagnostics industry by creating a new class of wholly non-invasive urine tests that can provide the same or far more powerful diagnostic information than existing diagnostics that use blood or tissue. It has already acquired an impressive patent portfolio to aggressively launch itself as a low cost alternative to blood tests.
"The Company believes that its Tr-DNA technology platform will enable more sensitive, accurate and affordable testing methods that can be conducted on simple urine samples, to create a wide range of biomedical applications, including prenatal tests for fetal genetic abnormalities, and for infectious diseases such as HIV, TB and other parasitic infections."
The report may be viewed in its entirety by visiting: http://BeaconEquityResearch.com
Registration is free.
Beacon Equity Research, LLC is a fee-based, comprehensive investment research firm, focusing primarily on the underserved small-cap sector. All Beacon analysts are seasoned industry professionals and adhere to the CFA Institute's (CFAI) stringent ethics and standards of practice guidelines. Beacon Research does not have any investment banking relationships with any of the companies covered. All analysts are compensated prior to performing their investment research and are not compensated in any way based on the future performance of the equities they follow.
Both Beacon Equity Research and Investrend subscribe to the "Standards for Independent Research Providers" at http://www.firstresearchconsortium.com. Beacon Research has been compensated a total of $18,000 by Xenomics, Inc. for a one-year enrollment in its research program.
Forward-Looking Statements
Certain statements made in this press release are forward looking. Such statements are indicated by words such as "expect," "might," "should," "anticipate" and similar words indicating uncertainty in facts and figures. Although Xenomics believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to be correct. As discussed in the periodic reports of Xenomics, as filed with the Securities and Exchange Commission, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: uncertainties associated with product development, the risk that Xenomics will not obtain approval to market its products, the risk that Xenomics' technology will not gain market acceptance, the risks associated with dependence upon key personnel, and the need for additional financing.